Trials / Recruiting
RecruitingNCT06947304
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (estimated)
- Sponsor
- Corcept Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Detailed description
Approximately 8 patients who are eligible for participation in the study will be assigned to a single dose cohort receiving 100 mg of miricorilant daily. The total duration of participation for each patient is expected to be up to 16 weeks, comprising a 6-week screening period, a 6-week treatment phase, and a 4-week follow-up period.
Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Miricorilant | 100 mg administered orally, once daily |
Timeline
- Start date
- 2025-08-22
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2025-04-27
- Last updated
- 2026-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06947304. Inclusion in this directory is not an endorsement.